OZBKD:OTC-OZBKD (USD)

COMMON STOCK | Others |

Last Closing

USD 0.265

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CSTNL iShares VII Public Limited Com..

+2.34 (+0.39%)

USD 32.85B
ZKBGF ZKB Gold ETF

N/A

USD 8.96B
TOETF Tosei Corporation

N/A

USD 7.70B
EFMSF ETFS Metal Securities Limited ..

N/A

USD 7.39B
ETHE Grayscale Ethereum Trust (ETH)

+0.66 (+3.32%)

USD 4.33B
MAWAF MAWAF

N/A

USD 3.65B
EBCRY EBCRY

+0.31 (+2.90%)

USD 3.54B
SSEEF SSgA SPDR ETFs Europe I Public..

N/A

USD 2.95B
IFXAF iShares Asia Trust - iShares F..

N/A

USD 2.94B
ZKBHF ZKB Gold ETF

N/A

USD 2.93B

ETFs Containing OZBKD

ZUB:CA BMO Equal Weight US Banks.. 99.89 % 0.38 %

+0.72 (+2.49%)

CAD 0.30B

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike